Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single-Dose Subcutaneous Administration of MEDI-528

A Phase I, Open Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single-Dose Subcutaneous Administration of MEDI-528, a Humanized Monoclonal Anti-Interleukin-9 Antibody, in Healthy Adult Volunteers

A Phase I studyto evaluate the safety and tolerability of escalating subcutaneous (SC) doses of MEDI-528 in to healthy adult volunteers.

Study Overview

• Status: Completed
• Conditions: Healthy
• Intervention / Treatment: Biological: MEDI-528 0.3 mg/kg; Biological: MEDI-528 1 mg/kg; Biological: MEDI-528 3 mg/kg; Biological: MEDI-528 9 mg/kg

Detailed Description

The primary objective of this Phase I study is to evaluate the safety and tolerability of escalating single SC doses of MEDI-528 administered to healthy adult volunteers in four dose groups.

• Study Type: Interventional
• Enrollment (Actual): 29
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Louisiana
    • New Orleans, Louisiana, United States, 70119
      • MDS Pharma Services
  • Nebraska
    • Lincoln, Nebraska, United States, 68502
      • MDS Pharma Services

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 19 years to 49 years (Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Males and females age 19 up to, and including, 49 years of age at the time of the first dose of study drug
• Weight less than 89 kg
• Written informed consent obtained from the volunteer
• Healthy by medical history and physical examination
• Sexually active females, unless surgically sterile or at least two years post-menopausal or an FSH≥40 mIu/mL, must use an effective method of avoiding pregnancy (including oral, injectable, transdermal, abstinence, use of a condom by the sexual partner or sterile sexual partner) for 3 months before the first dose of study drug, and must agree to continue using such precautions through the study period of 84 days. Cessation of birth control after this point should be discussed with a responsible physician. Sexually active males, unless surgically sterile, must likewise use an effective method of birth control (condom or abstinence) and must agree to continue using such precautions through Study Day 84 after their dose of study drug.
• Use of common over-the-counter medications such as topical corticosteroids, decongestants, antihistamines, analgesics, and antacids is permitted unless, in the opinion of the investigator, it would interfere with either the volunteer's ability to complete the study or interpretation of the study results.
• Ability to complete the follow-up period of 84 days
• Willing to forego other forms of experimental treatment during the study period of 84 days
• Willing to forego vigorous activity 1 - 2 days before dosing, and before each study visit.

Exclusion Criteria:

• Acute illnesses or evidence of significant active infection, such as fever greater than or equal to 38.0 C (100.5°F) at the start of the study
• Use of prescription medications, other than oral contraceptives, in the 28-day period before Study Day 0
• Any blood donation or significant loss of blood within 6 months of time of entry into the study
• History of immunodeficiency or receipt of immunosuppressive drugs
• History of allergy or reaction to any component of the MEDI-528 formulation
• History of substance abuse that, in the opinion of the investigator, may compromise the ability of the study subject to complete the study and follow-up period
• Evidence of any systemic disease, neurologic abnormality, lymphadenopathy, or splenomegaly upon physical examination
• Evidence of infection with hepatitis A, B, or C virus or HIV-1
• Receipt of immunoglobulins or blood products within 60 days of entering the study
• Receipt of any investigational drug therapy or standard vaccine therapy, other than vaccination for influenza, within 60 days of the first dose of study drug through Study Day 84 (use of licensed agents for indications not listed in the package insert is permitted)
• Receipt of MEDI-528 in any previous clinical study
• At Screening (must be within 21 days before study dose administration) any of the following: Hgb, total WBC, platelet count, Na, K, C1, CO2, AST, ALT, BUN, glucose, amylase, lipase, creatinine, or troponin out of the normal range; other abnormal laboratory values in the screening panel that, in the opinion of the principal investigator, are judged to be clinically significant
• Clinically significant abnormality, as determined by the investigator, on 12-lead electrocardiogram at the time of initial screening
• Clinically significant abnormalities noted on baseline brain MRI
• Elective surgery planned during the study period through Study Day 84
• Pregnancy (sexually active females must have a negative serum pregnancy test on the day of the first dose of study drug, before dosing)
• Nursing mother
• The presence of any condition or concern which, in the opinion of the investigator, may interfere with the conduct or interpretation of the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: MEDI-528 0.3 mg/kg; MEDI-528 (0.3 mg/kg) administered as a single, subcutaneous (SC) dose	Biological: MEDI-528 0.3 mg/kg; MEDI-528 (0.3 mg/kg) administered as a single, subcutaneous (SC) dose
Experimental: MEDI-528 1 mg/kg; MEDI-528 (1 mg/kg) administered as a single, SC dose	Biological: MEDI-528 1 mg/kg; MEDI-528 (1 mg/kg) administered as a single, SC dose
Experimental: MEDI-528 3 mg/kg; MEDI-528 (3 mg/kg) administered as a single, SC dose	Biological: MEDI-528 3 mg/kg; MEDI-528 (3 mg/kg) administered as a single, SC dose
Experimental: MEDI-528 9 mg/kg; MEDI-528 (9 mg/kg) administered as a single, SC dose	Biological: MEDI-528 9 mg/kg; MEDI-528 (9 mg/kg) administered as a single, SC dose

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of Adverse Events	Number of participants experiencing adverse events (includes both adverse events and serious adverse events)	Days 0 - 84
Incidence of Abnormal Troponin Levels	Number of participants with troponin levels greater than upper limit of normal	Days 0, 1, 7, 14, and 28
Incidence of Clinically Significant Changes From Baseline in Neurologic Exam	Number of participants with clinically significant changes from baseline in neurologic exam	Days 0, 7, 14, 21, 28, 42, and 84
Incidence of Changes From Baseline in the Day 28 Magnetic Resonance Imaging (MRI) of the Brain	Number of participants with changes from baseline in the Day 28 MRI of the brain	Days 0 and 28
Incidence of Serious Adverse Events	Number of participants experiencing serious adverse events	Days 0 - 84

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of Anti-drug Antibodies (ADA) to MEDI-528	Number of participants with ADA to MEDI-528	Days 0, 14, 28, 42, and 84
Time to Observed Maximum Serum Concentration (Tmax)	Tmax of MEDI-528	Days 0, 1, 2, 3, 4, 5, 7, 10, 14, 21, 28, 42, and 84
Observed Maximum Serum Concentration (Cmax)	Cmax of MEDI-528	Days 0, 1, 2, 3, 4, 5, 7, 10, 14, 21, 28, 42, and 84
Area Under the Concentration Curve From Time Zero to Last Measurable Concentration [AUC(0-t)]	AUC(0-t) of MEDI-528	Days 0, 1, 2, 3, 4, 5, 7, 10, 14, 21, 28, 42, and 84
Area Under the Concentration Curve From Time Zero to Infinity [AUC(0-infinity)] of MEDI-528	AUC(0-infinity) of MEDI-528	Days 0, 1, 2, 3, 4, 5, 7, 10, 14, 21, 28, 42, and 84
Percent of Total Area Under the Concentration Curve Extrapolated From Last Measurable Time to Infinity [AUC(Ext)]	AUC(ext) of MEDI-528	Days 0, 1, 2, 3, 4, 5, 7, 10, 14, 21, 28, 42, and 84
Total Body Clearance (CL)	CL of MEDI-528	Days 0, 1, 2, 3, 4, 5, 7, 10, 14, 21, 28, 42, and 84
Half-life (T1/2)	T1/2 of MEDI-528	Days 0, 1, 2, 3, 4, 5, 7, 10, 14, 21, 28, 42, and 84
Apparent Extravascular Terminal Phase Volume of Distribution (Vz/F)	Vz/F of MEDI-528	Days 0, 1, 2, 3, 4, 5, 7, 10, 14, 21, 28, 42, and 84

Collaborators and Investigators

• Sponsor: MedImmune LLC
• Investigators: Study Director: Barbara White, M.D., MedImmune LLC

Publications and helpful links

General Publications

• White B, Leon F, White W, Robbie G. Two first-in-human, open-label, phase I dose-escalation safety trials of MEDI-528, a monoclonal antibody against interleukin-9, in healthy adult volunteers. Clin Ther. 2009 Apr;31(4):728-40. doi: 10.1016/j.clinthera.2009.04.019.

Study record dates

Study Major Dates

• Study Start: June 1, 2005
• Primary Completion (Actual): April 1, 2006
• Study Completion (Actual): July 1, 2006

Study Registration Dates

• First Submitted: June 27, 2005
• First Submitted That Met QC Criteria: June 27, 2005
• First Posted (Estimate): June 28, 2005

Study Record Updates

• Last Update Posted (Estimate): December 11, 2013
• Last Update Submitted That Met QC Criteria: October 17, 2013
• Last Verified: October 1, 2013

More Information

Terms related to this study

• Other Study ID Numbers: MI-CP109